- $204.66m
- -$357.71m
- 22
- 49
- 36
- 28
Annual income statement for Acelyrin, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS/A | PROSPECTUS/A | 10-K |
| Standards: | USG | USG | USG |
| Status: | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||
| Research And Development | |||
| Total Operating Expenses | 41.8 | 69.2 | 422 |
| Operating Profit | -41.8 | -69.2 | -422 |
| Total Net Non Operating Interest Income / Expense | |||
| Other Net Non Operating Costs | |||
| Net Income Before Taxes | -41.8 | -64.8 | -382 |
| Net Income After Taxes | -41.8 | -64.8 | -382 |
| Net Income Before Extraordinary Items | |||
| Net Income | -41.8 | -64.8 | -382 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||
| Income Available to Common Shareholders Including Extraordinary Items | |||
| Diluted Net Income | -41.8 | -64.8 | -382 |
| Diluted Weighted Average Shares | |||
| Basic EPS Including Extraordinary Items | |||
| Diluted EPS Including Extraordinary Items | |||
| Diluted EPS Excluding Extraordinary Items | |||
| Normalised Income Before Taxes | |||
| Normalised Income After Taxes | |||
| Normalised Income Available to Common Shareholders | |||
| Diluted Normalised EPS | -0.451 | -0.699 | -3.88 |
| Dividends per Share |